Navigation Links
Laureate Pharma Reports Record Growth for 2007

Continued Momentum Results in 131.4% Increase in Revenue and Positive

EBITDA for Three Consecutive Quarters

PRINCETON, N.J., April 1 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced record growth in revenues for 2007. The company posted a 131.4% increase over the same period last year and generated positive EBITDA for the third consecutive quarter. Laureate achieved other milestones in 2007, including a commissioned new Pilot Plant, an expanded facility that includes a new warehouse, a 30% increase in the company's workforce, a new strategic alliance, and the election of a new non-executive Chairman. In addition, the company signed major biopharmaceutical development and manufacturing agreements and several fill/finish agreements. Collectively, these factors position the company for continued growth and momentum for 2008 and beyond.

(Logo: )

"We continue to see strong growth in our client base and increasing demand for contract manufacturing services," said Robert Broeze, President and Chief Executive Officer at Laureate Pharma. "Laureate Pharma has superior bioprocessing capabilities specifically focused on monoclonal antibodies and recombinant proteins expressed in mammalian cells. We help our clients get the most out of their biopharmaceutical development programs by enabling them to capitalize on our expertise and experience in the areas of biopharmaceutical development and production. This inevitably helps them to get their new products into the clinic faster. We are excited about our continued business momentum and are extremely pleased with Laureate's overall performance in 2007. We are on track for another record year in 2008."

"Laureate Pharma grew their revenue 131.4% year-over-year and reported three consecutive quarters of EBITDA positive results," said James A. Datin, Executive Vice President and Managing Director of the Life Sciences Group at Safeguard Scientifics. "This represents a solid performance from a solid company. We are delighted with Laureate's milestones and achievements and look forward to seeing their continued growth." Safeguard Scientifics acquired Laureate in December 2004, providing the company with growth capital, operational and management support to achieve its strategic plan.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or or visit

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS), Technology-Enabled Services and Internet- based Businesses, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.

SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/23/2015)... Calif., Nov. 23, 2015   Ceres, Inc . ... today financial results for the fiscal year ended August ... --> --> During ... forage and feed products with a better balance of ... signed distribution agreements with several leading crop input providers ...
(Date:11/23/2015)... ... November 23, 2015 , ... Shimadzu ... of its Nexera UC Unified Chromatography system. The award from R&D magazine recognizes ... products of the year in the analytical and testing category. R&D Magazine chose ...
(Date:11/23/2015)... 2015 The royalty-free a ... to develop daclatasvir for 112 low- and m ... --> --> The Medicines Patent Pool ... medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a ... genotypes of the HCV virus.  The royalty-free licence will enable ...
(Date:11/23/2015)... 23, 2015 biochar market ... 2015, and it is expected to grow with a ... driving the growth of the global market include improved ... of biochar, increased government initiatives and stringent environmental regulations, ... stringent environment regulations are the key drivers for the ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
Breaking Biology News(10 mins):